Doximity Inc. (NYSE: DOCS) reported fiscal first-quarter results that exceeded revenue expectations, driven by robust adoption of its artificial intelligence products and an expanded total addressable market in healthcare. The digital healthcare company posted revenue of $156.6 million, up 7% year over year, beating the analyst consensus estimate of $151.7 million. This performance reflects a broader commercial opportunity unlocked by AI, which CEO Jeff Tangney described as a "real surprise and upside" for the business. The positive reception was amplified by a short squeeze, with shares surging 34.29% to $27.74 on Friday, given that over 16% of the public float was sold short.

The company’s adjusted EBITDA totaled $74.8 million, representing a 48% margin. Earnings per share were 29 cents, slightly below the consensus estimate of 30 cents. Despite the minor miss on EPS, the strong top-line growth and margin expansion underscored the effectiveness of Doximity’s strategy to integrate AI into clinical workflows. Tangney noted that AI is "up-leveling our business across the board," enabling deeper engagement with senior executives at pharmaceutical companies.

AI Products Drive Growth

Doximity’s clinical AI assistant, Doximity Ask, emerged as a key growth driver, achieving the lowest clinical error rates and highest safety ratings among tested U.S.-based models in the NOHARM benchmark. The product recorded a 4.8% error rate compared to 13.6% for Anthropic’s leading model. This performance has facilitated broader adoption across health systems, with 165 health system clients now using Doximity’s AI offerings. Workflow active prescriber growth exceeded 30% year over year, while AI Search queries increased more than 25% sequentially.

Financial Outlook and Investment Strategy

CFO Matt Sonefeldt stated that stronger-than-expected AI adoption by clinicians prompted Doximity to increase AI investments during fiscal 2027 to support long-term growth opportunities. The company ended the quarter with 127 pharmaceutical and hospital customers generating more than $500,000 in annual subscription revenue on a trailing 12-month basis.

For the fiscal second quarter, Doximity expects revenue of $170 million to $171 million, compared with the analyst consensus estimate of $171.9 million. The company raised its full-year fiscal 2027 revenue guidance to a range of $671 million to $681 million, up from the prior outlook of $664 million to $676 million. This updated forecast exceeds the consensus estimate of approximately $670.3 million.

What the Numbers Show

The divergence between the slight miss on earnings per share and the significant beat on revenue highlights a strategic shift in capital allocation. While operational efficiency remains high with a 48% adjusted EBITDA margin, the company is actively reinvesting in AI infrastructure to capture larger commercial opportunities. The sequential jump in AI Search queries (>25%) alongside record engagement suggests that the initial investment phase is yielding tangible user adoption metrics, validating the decision to raise full-year guidance despite near-term pressure on bottom-line estimates.

Piper Sandler analyst Jessica Tassan has reiterated an Overweight rating on Doximity Inc. (NYSE: DOCS) and raised its price target from $42 to $47. The adjustment signals increased confidence in the company’s growth trajectory and market position within the healthcare technology sector. For investors holding or considering shares of Doximity, the higher price target suggests potential upside from current trading levels, reinforcing the firm’s bullish stance.

Analyst Action Details

The research note maintains the existing recommendation while adjusting the valuation metric. This is a common practice when analysts believe a stock’s fundamentals have strengthened or when broader market conditions favor the sector, even if the core investment thesis remains unchanged.

Market Implications

The raise in the price target by $5 represents approximately a 11.9% increase in the firm’s expected fair value for Doximity. While the source document does not specify the underlying drivers for this change, such adjustments often follow positive earnings reports, new product launches, or favorable industry trends. Investors typically monitor these updates as signals of institutional sentiment.

What the Numbers Show

The consistent Overweight rating indicates that Piper Sandler views Doximity as undervalued relative to its peers or intrinsic worth. The upward revision in the price target narrows the gap between current market pricing and the analyst’s projected value, potentially attracting further institutional interest if the stock trades below the new $47 benchmark.